Archford Capital Strategies LLC Boosts Holdings in Johnson & Johnson $JNJ

Archford Capital Strategies LLC lifted its stake in shares of Johnson & Johnson (NYSE:JNJ) by 47.4% during the 3rd quarter, Holdings Channel.com reports. The institutional investor owned 13,475 shares of the company’s stock after buying an additional 4,331 shares during the period. Archford Capital Strategies LLC’s holdings in Johnson & Johnson were worth $2,498,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also bought and sold shares of JNJ. Lifestyle Asset Management Inc. boosted its position in shares of Johnson & Johnson by 3.4% during the third quarter. Lifestyle Asset Management Inc. now owns 1,683 shares of the company’s stock valued at $312,000 after purchasing an additional 56 shares in the last quarter. Wynn Capital LLC lifted its position in Johnson & Johnson by 0.4% during the 3rd quarter. Wynn Capital LLC now owns 15,930 shares of the company’s stock valued at $2,954,000 after acquiring an additional 57 shares during the period. Defined Financial Planning LLC lifted its position in Johnson & Johnson by 3.0% during the 3rd quarter. Defined Financial Planning LLC now owns 1,926 shares of the company’s stock valued at $365,000 after acquiring an additional 57 shares during the period. W.H. Cornerstone Investments Inc. grew its holdings in Johnson & Johnson by 0.7% in the second quarter. W.H. Cornerstone Investments Inc. now owns 7,896 shares of the company’s stock worth $1,206,000 after purchasing an additional 58 shares during the period. Finally, YANKCOM Partnership grew its holdings in Johnson & Johnson by 0.8% in the second quarter. YANKCOM Partnership now owns 7,042 shares of the company’s stock worth $1,076,000 after purchasing an additional 58 shares during the period. 69.55% of the stock is currently owned by hedge funds and other institutional investors.

Johnson & Johnson Stock Down 0.3%

JNJ opened at $206.93 on Wednesday. The stock has a market capitalization of $498.56 billion, a price-to-earnings ratio of 19.97, a PEG ratio of 2.25 and a beta of 0.36. The firm has a 50 day moving average price of $200.25 and a 200-day moving average price of $181.93. Johnson & Johnson has a twelve month low of $140.68 and a twelve month high of $215.18. The company has a quick ratio of 0.80, a current ratio of 1.07 and a debt-to-equity ratio of 0.50.

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Wednesday, August 30th. The company reported $2.26 EPS for the quarter. The business had revenue of $24.02 billion during the quarter. Johnson & Johnson had a net margin of 27.26% and a return on equity of 32.73%. Equities research analysts forecast that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Tuesday, December 9th. Shareholders of record on Tuesday, November 25th were issued a $1.30 dividend. The ex-dividend date of this dividend was Tuesday, November 25th. This represents a $5.20 dividend on an annualized basis and a yield of 2.5%. Johnson & Johnson’s dividend payout ratio is currently 50.19%.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on JNJ. HSBC reissued a “buy” rating and issued a $240.00 price target on shares of Johnson & Johnson in a research report on Wednesday, December 10th. The Goldman Sachs Group boosted their target price on Johnson & Johnson from $213.00 to $240.00 and gave the stock a “buy” rating in a report on Thursday, December 18th. Morgan Stanley raised their price target on Johnson & Johnson from $190.00 to $197.00 and gave the company an “equal weight” rating in a report on Friday, December 12th. Royal Bank Of Canada set a $240.00 price target on shares of Johnson & Johnson in a research note on Wednesday, December 17th. Finally, Weiss Ratings restated a “buy (b)” rating on shares of Johnson & Johnson in a research note on Friday, October 31st. Four research analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and nine have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $211.25.

Johnson & Johnson Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.